SNOA - オクルス・イノベイティブ・サイエンス (Sonoma Pharmaceuticals Inc.)

SNOAのニュース

   Sonoma Pharmaceuticals to Present at Upcoming Spring Virtual Investor Conferences  2021/03/04 22:03:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that CEO Amy Trombly and CFO Jerry Dvonch will present at the following upcoming virtual conferences. Event H.C. Wainwright Global Life Sciences Conference Date March 9-10, 2021
   Sonoma Pharmaceuticals Reports Third Quarter FY 2021 Financial Results  2021/02/16 22:30:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care and dermatological conditions today announced financial results for its third fiscal quarter and nine months ended December 31, 2020. “We continue to effectively execute our business plan of increasing revenue while reducing our expense
   Keloid Treatment Market to See Fabulous Rise by 2027 with Novartis AG, Sensus Healthcare, RXi Pharmaceuticals, Inc., Sonoma Pharmaceuticals, Inc. | FMI Report  2021/02/16 17:54:48 OpenPR
According to the latest market report published by FMI titled‘Keloid Treatment Market: Global Industry Analysis (2012-2016) and Opportunity Assessment (2017-2027),’the global keloid treatment market is estimated to be worth US$ 3,145.8 Mn by 2017 end, and is expected to expand
   BREAKING ALERT: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – SNOA - Stocks News Feed  2021/02/15 20:45:00 Stocks News Feed
NEW YORK, Feb. 15, 2021 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Sonoma… Read More »BREAKING ALERT: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – SNOA
   Sonoma Pharmaceuticals and Microderm Technologies Announce that Dermodacyn® Disinfecting Solution is Now Available in Hong Kong and Thailand  2021/01/28 21:30:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, disinfectant use and dermatological conditions, and Microderm Technologies Ltd. announce that Dermodacyn® disinfectant has received import clearance as a medical device for Thailand with the help from Microderm’s partner VetSynova Co.
   ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. – SNOA  2020/12/24 21:07:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma’s “unaudited condensed consolidate
   Why Sonoma, Medicenna And Dare Bioscience Are Trading Higher Today  2020/12/18 17:13:40 Benzinga
Sonoma Pharmaceuticals (NASDAQ: SNOA ) shares are … Full story available on Benzinga.com
   Sonoma Pharmaceuticals Announces Partnership with Gabriel Science, LLC For Dental Markets  2020/12/17 21:10:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Gabriel Science enter into distribution agreement for the sale of HOCl-products into the dental markets.
   SNOA Stock: Sonoma Pharmaceuticals Heads up on Partnership News  2020/12/11 14:16:02 CNA Finance
SNOA stock is headed for the top in the market after announcing it has entered into a new partnership with Crown Laboratories.
   Sonoma Pharmaceuticals and Crown Laboratories Announce an Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products  2020/12/10 21:10:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Crown Laboratories announce an exclusive partnership to launch Microcyn® Technology-based anti-itch OTC products.
   ROSEN, A LEADING INVESTOR FIRM, Continues To Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. – SNOA  2020/12/24 21:07:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) resulting from allegations that Sonoma may have issued materially misleading business information to the investing public. On November 17, 2020, after market hours, Sonoma filed a Form 8-K with the U.S. Securities and Exchange Commission announcing that Sonoma’s “unaudited condensed consolidate
   Why Sonoma, Medicenna And Dare Bioscience Are Trading Higher Today  2020/12/18 17:13:40 Benzinga
Sonoma Pharmaceuticals (NASDAQ: SNOA ) shares are … Full story available on Benzinga.com
   Sonoma Pharmaceuticals Announces Partnership with Gabriel Science, LLC For Dental Markets  2020/12/17 21:10:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Gabriel Science enter into distribution agreement for the sale of HOCl-products into the dental markets.
   SNOA Stock: Sonoma Pharmaceuticals Heads up on Partnership News  2020/12/11 14:16:02 CNA Finance
SNOA stock is headed for the top in the market after announcing it has entered into a new partnership with Crown Laboratories.
   Sonoma Pharmaceuticals and Crown Laboratories Announce an Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products  2020/12/10 21:10:00 Business Wire
WOODSTOCK, Ga.--(BUSINESS WIRE)--Sonoma Pharmaceuticals and Crown Laboratories announce an exclusive partnership to launch Microcyn® Technology-based anti-itch OTC products.

calendar